why choose us

First received: September 21, 2023

Clinical Trial: Recombinant vWF Concentrate and ECMO

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Bleeding Disorder

Study Type: INTERVENTIONAL


Official Title: Safety and Tolerability of Recombinant Von Willebrand Factor Concentrate in Adult ECMO Patients With Major Bleeding: A Phase I Study

Brief Summary: Adult patients on extracoporeal membrane oxygenation (ECMO) frequently experience bleeding, which is in part caused by acquired von Willebrand syndrome (vWS).Prior in vitro studies have shown that the addition of recombinant von Willebrand Factor (vWF) to ECMO patient blood samples, normalizes platelet adhesion and thrombus formation.This study is a phase I study, where adult ECMO patients with refractory bleeding will be treated with recombinant vWF a single time.The primary objectives are to evaluate the safety,…

Read more